Gail J. Roboz
NewYork–Presbyterian Hospital
444 Papers
1.6K Citations
Gail J. Roboz is an academic researcher from NewYork–Presbyterian Hospital. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 53, co-authored 339 publications. Previous affiliations of Gail J. Roboz include Cornell University & Boston Medical Center.
Chat about Author
Papers
Differential Response to Hypomethylating Agents Based on Sex: A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)
Amy E. DeZern,Amer M. Zeidan,John Barnard,Wesley Hand,Najla Al Ali,Francis Brown,Cassie Zimmerman,Gail J. Roboz,Rami S. Komrokji,Guillermo Garcia-Manero,David P. Steensma,Mikkael A. Sekeres +11 more
TL;DR: Women with higher-risk MDS may live longer when treated with DAC than with AZA, and future prospective investigations of both drugs in men and women are warranted.
3
Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium
Rami S. Komrokji,Mikkael A. Sekeres,John Barnard,Najla Alali,Amy E. DeZern,Eric Padron,David A. Sallman,Jeffrey E. Lancet,Gail J. Roboz,Jaime Fensterl,Guillermo Garcia-Manero,David P. Steensma,Alan F. List +12 more
TL;DR: LEN yields a higher rate of HI-E in LR- MDS when used as first line therapy, but responses to HMAs were similar when used before or after LEN, and the order of treatment still did not impact overall survival.
3
Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.
Hartmut Döhner,Andrew H. Wei,Pau Montesinos,Hervé Dombret,Farhad Ravandi,Hamid Sayar,Kimmo Porkka,Irwindeep Sandhu,Francesco Passamonti,Fabrizio Pane,Tadeusz Robak,Jose F Falantes,Andre C. Schuh,Gert J. Ossenkoppele,Ignazia La Torre,Barry Skikne,Keshava Kumar,Qian Dong,C.L. Beach,Gail J. Roboz +19 more
TL;DR: CC-486 is an oral hypomethylating agent that reduces the risk of relapse in patients with recurrent AML by suppressing growth of residual leukemic cells post-induction.
3
Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response
Karen W.L. Yee,Gail J. Roboz,Casey O'Connell,Elizabeth A. Griffiths,Raoul Tibes,Katherine Walsh,Wendy Stock,Guillermo Garcia-Manero,Michael R. Savona,Farhad Ravandi,Naval Daver,Elias Jabbour,Todd L. Rosenblat,Jean Pierre J. Issa,Xiang Yao Su,Mohammad Azab,Hagop M. Kantarjian +16 more
TL;DR: The landmark methodology avoids the bias of early deaths before cycles 4 and 6 attributing a survival benefit in those who did not die early and were able to get more cycles, and more interestingly the landmark OS benefit in patients who received at least 4 or 6 cycles was also evident in patientsWho did not have an objective CRc.
3